Skip to main content
    A

    Arcadia Biosciences Inc (RKDA)

    Official site

    CONSUMER DEFENSIVE • PACKAGED FOODS • NASDAQ

    $0.19
    -0.02 (-11.19%)

    Market Cap: $1.32M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Arcadia Biosciences Inc (RKDA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Arcadia Biosciences reported revenue of $4.86M for the fiscal year ended Dec 31, 2025, down 3.7% from the year before. That year, net income was -$2.34M with a net margin of -48.1%, operating cash flow was -$4.74M and free cash flow was -$4.74M. The quarter ended Sep 30, 2026 had revenue of $1.62M and net income of $1.75M.

    Revenue and Margins

    The operating margin was -51.5% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $3.19M, a compound annual rate of 4.8%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$4.86M-3.7%36.2%-51.5%-48.1%
    Dec 2024$5.04M+13.3%41.3%-72.3%-139.5%
    Dec 2023$4.45M-40.0%51.2%-137.0%-314.0%
    Dec 2022$7.42M+9.4%17.8%-188.8%-210.5%
    Dec 2021$6.78M-15.6%-28.4%-524.0%-238.0%
    Dec 2020$8.03M+587.3%35.3%-159.0%-75.0%
    Dec 2019$1.17M-20.2%24.3%-1657.9%-2469.9%
    Dec 2018$1.46M-63.6%100.0%-1152.3%-1841.5%
    Dec 2017$4.03M+26.3%100.0%-355.6%-390.1%
    Dec 2016$3.19MN/A71.9%-584.1%-615.6%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income rose 104.4% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$4.86M$5.04M$4.45M$7.42M$6.78M$8.03M$1.17M$1.46M$4.03M$3.19M
    Cost of revenue$3.10M$2.96M$2.17M$6.10M$8.71M$5.20M$885.00K$0$0$895.00K
    Gross profit$1.76M$2.08M$2.28M$1.32M-$1.93M$2.83M$284.00K$1.46M$4.03M$2.29M
    Research and development$9.00K$53.00K$64.00K$1.51M$3.89M$7.96M$7.10M$6.07M$7.41M$8.66M
    Operating income-$2.50M-$3.65M-$6.10M-$14.01M-$35.53M-$12.78M-$19.38M-$16.87M-$14.31M-$18.62M
    Net income-$2.34M-$7.04M-$13.99M-$15.61M-$16.13M-$6.03M-$28.87M-$26.96M-$15.71M-$19.62M
    EBITDA-$2.47MN/A$1.04M-$9.74M-$13.02M-$3.80MN/A-$10.95M-$13.75M-$17.64M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$1.62M$1.44M$1.10M$901.00K$1.30M$1.46M$1.20M$1.22M$1.54M$1.31M$987.00K$627.00K
    Gross profit$859.00K$631.00K$400.00K$193.00K$418.00K$631.00K$518.00K$388.00K$505.00K$673.00K$516.00K$609.00K
    Operating income-$839.00K-$496.00K-$779.00K-$1.38M-$1.15M-$501.00K$530.00K-$2.28M-$1.76M$1.98M-$1.59M$616.00K
    Net income$1.75M-$6.27M-$4.38M-$1.34M$856.00K-$4.46M$2.60M-$4.06M-$1.61M$1.06M-$2.42M-$2.85M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $259.00K were 4.0% of total assets of $6.55M, against total liabilities of $2.41M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$6.55M$13.52M$19.70M$28.92M$43.92M$47.35M$32.57M$24.02M$16.57M$56.57M
    Current assets$6.36M$9.24M$14.97M$25.40M$35.39M$31.70M$28.44M$22.88M$15.05M$52.22M
    Cash and equivalents$259.00K$4.24M$6.52M$20.64M$28.68M$14.04M$8.42M$12.00M$9.13M$2.01M
    Total liabilities$2.41M$7.29M$7.00M$8.02M$12.72M$18.80M$24.25M$11.21M$8.56M$34.38M
    Short-term debtN/A$155.00K$852.00K$1.01M$1.07M$1.14M$24.00K$29.00KN/A$25.13M
    Long-term debtN/AN/AN/AN/AN/A$2.10M$107.00KN/A$0$25.13M
    Shareholder equity$4.14M$6.22M$12.84M$21.03M$31.09M$27.73M$7.71M$12.81M$8.01M$22.20M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$4.72M$5.89M$5.32M$6.55M$8.58M$7.79M$12.99M$13.52M$15.24M$17.37M$16.05M$19.70M
    Total liabilities$2.31M$5.26M$2.44M$2.41M$3.14M$3.25M$4.08M$7.29M$5.09M$5.80M$5.56M$7.00M
    Cash and equivalents$2.84M$4.18M$954.00K$259.00K$1.12M$1.38M$3.16M$4.24M$3.94M$5.50M$3.32M$6.52M
    Shareholder equity$2.40M$633.00K$2.88M$4.14M$5.44M$0$0$6.22M$10.29M$11.70M$10.62M$12.84M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$4.74M-$9.63M-$15.29M-$13.98M-$25.87M-$30.22M-$17.20M-$13.63M-$13.96M-$17.05M
    Capital expenditures$0$16.00K$5.00K$72.00K$1.01M$2.33M$1.48M$250.00K$79.00K$231.00K
    Free cash flow-$4.74M-$9.64M-$15.30M-$14.05M-$26.88M-$32.55M-$18.68M-$13.88M-$14.04M-$17.29M
    Share repurchasesN/AN/AN/AN/AN/AN/AN/A$1.31MN/AN/A
    Investing cash flow$750.00K$7.34M-$4.34M$1.42M$16.61M$17.28M-$8.37M-$5.97M$47.18M-$5.30M
    Financing cash flow$6.00K$9.00K$5.51M$4.52M$21.90M$20.56M$21.99M$22.48M-$26.10M$396.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$1.28M-$319.00K-$1.10M-$861.00K-$257.00K-$2.03M-$1.59M-$2.21M-$1.75M-$2.46M-$3.21M-$4.14M
    Capital expendituresN/AN/A$0$0$0$0$0$0$2.00M$3.00K$13.00K$52.00K
    Free cash flowN/AN/A-$1.10M-$861.00K-$257.00K-$2.03M-$1.59M-$2.21M-$3.75M-$2.46M-$3.22M-$4.20M
    Last 12 quarters

    Frequently Asked Questions About RKDA

    What is Arcadia Biosciences' annual revenue?

    Arcadia Biosciences reported revenue of $4.86M for the fiscal year ended Dec 31, 2025.

    How fast is Arcadia Biosciences' revenue growing?

    Revenue was down 3.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -13.2%.

    Is Arcadia Biosciences profitable?

    No. Arcadia Biosciences reported net income of -$2.34M for the fiscal year ended Dec 31, 2025, with a net margin of -48.1%.

    How much free cash flow does RKDA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$4.74M minus capital expenditures of $0 produced free cash flow of -$4.74M.

    How much debt does Arcadia Biosciences have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $259.00K.